NIVOLUMAB WITH AZACYTIDINE IN PEDIATRIC RELAPSED/REFRACTORY AML:PHASE I RESULTS FROM TACL CONSORTIUM

被引：0
|
作者：
Verma, Anupam [1 ]
Chi, Yueh-Yun [1 ]
Malvar, Jemily [1 ]
Lamble, Adam [1 ]
Chaudhury, Sonali [1 ]
Sung, Lillian [1 ]
Agarwal, Archana [1 ]
Liang, Gangning [1 ]
Sposto, Richard [1 ]
Leong, Roy [1 ]
Brown, Patrick [1 ]
Kaplan, Joel [1 ]
Schafer, Eric [1 ]
Slone, Tamra [1 ]
Pauly, Melinda [1 ]
Chang, Bill [1 ]
Stieglitz, Elliot [1 ]
Wayne, Alan [1 ]
Hijiya, Nobuko [1 ]
Bhoywani, Deepa [1 ]
机构：
[1] Therapeut Adv Childhood Leukemia & Lymphoma, Salt Lake City, UT USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I trial of sirolimus (Rapamycin) in pediatric patients with relapsed/refractory leukemia
    Rheingold, Susan R.
    Sacks, Nancy
    Chang, Yuch J.
    Brown, Valerie I.
    Teachey, David T.
    Lange, Beverly J.
    Grupp, Stephan A.
    BLOOD, 2007, 110 (11) : 834A - 834A
  • [42] Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
    Pommert, Lauren
    Bhojwani, Deepa
    Sposto, Richard
    Florendo, Ellynore
    Schafer, Eric
    Gossai, Nathan
    Van Thu Huynh
    Rao, Sridhar
    Burke, Michael J.
    BLOOD, 2019, 134
  • [43] Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
    Tarlock, Katherine
    Liu, Xiaowei
    Minard, Charles G.
    Menig, Sarah
    Reid, Joel M.
    Isikwei, Emasenyie
    Bergeron, Sharon
    Horton, Terzah M.
    Fox, Elizabeth
    Weigel, Brenda
    Cooper, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712
    Tarlock, Katherine
    Liu, Xiaowei
    Minard, Charles G.
    Isikwei, Emasenyie A.
    Reid, Joel M.
    Horton, Terzah M.
    Fox, Elizabeth
    Weigel, Brenda J.
    Cooper, Todd
    PEDIATRIC BLOOD & CANCER, 2023, 70 (12)
  • [45] Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds
    Tsimberidou, Apostolia M.
    Culotta, Kirk
    Wistuba, Ignacio
    Fu, Siqing
    Naing, Aung
    Falchook, Gerald
    Piha-Paul, Sarina
    Zinner, Ralph
    Rodriguez-Canales, Jaime
    He, Guangan
    Siddik, Zahid H.
    Jelinek, Jaroslav
    Chung, Woonbok
    Ye, Yang
    Said, Rabih
    Hess, Kenneth
    Stewart, David J.
    Kurzrock, Razelle
    Issa, Jean-Pierre
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Terui, Yasuhito
    Yamamoto, Kazuhito
    Fukuhara, Noriko
    Choi, Ilseung
    Kuroda, Junya
    Ando, Kiyoshi
    Hattori, Akira
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
  • [47] Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium
    Schafer, Eric S.
    Chao, Karen
    Stevens, Alexandra M.
    Jo, Eunji
    Hilsenbeck, Susan G.
    Gossai, Nathan P.
    Doan, Andrew
    Colace, Susan I.
    Guinipero, Terri
    Otterson, Daniel
    Kaplan, Joel A.
    Hinson, Ashley
    Pommert, Lauren
    Wayne, Alan S.
    Bhojwani, Deepa
    Burke, Michael J.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
  • [48] A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study
    Malempati, S.
    Weigel, B.
    Ingle, A. M.
    Ahern, C. H.
    Carroll, J. M.
    Roberts, C. T., Jr.
    Fox, F. E.
    Voss, S.
    Adamson, P. C.
    Blaney, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Bartlett, Nancy L.
    Ramchandren, Radhakrishnan
    Vose, Julie M.
    Moskowitz, Alison J.
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Kato, Kazunobu
    Fong, Abraham
    Advani, Ranjana H.
    BLOOD, 2016, 128 (22)
  • [50] Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
    Abedin, Sameem
    Murthy, Guru Subramanian Guru
    Runaas, Lyndsey
    Michaelis, Laura C.
    Atallah, Ehab L.
    Hamadani, Mehdi
    Harrington, Alexandra M.
    Carlson, Karen
    BLOOD, 2019, 134
12345